Keyword: Summit Therapeutics

Summit, Sarepta in $584M-plus DMD pipeline license pact in Europe

Buoyed by its recent, and controversial, FDA approval for its Duchenne drug Exondys 51 (eteplirsen), Sarepta has signed a pact potentially worth more than half a billion dollars with the U.K.’s Summit Therapeutics, giving it rights to its Duchenne candidate in Europe and elsewhere.